Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB161734 plus chemotherapy in previously untreated KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma
NCT07522073Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Apr 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of INCB161734 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Incyte. Started Apr 2026; status: recruiting.
02
Drugs
INCB161734
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07522073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07522073.